PMID- 29402784
OWN - NLM
STAT- MEDLINE
DCOM- 20180911
LR  - 20181113
IS  - 1423-0224 (Electronic)
IS  - 0302-282X (Print)
IS  - 0302-282X (Linking)
VI  - 75
IP  - 4
DP  - 2017
TI  - Parallel Effects of Methamphetamine on Anxiety and CCL3 in Humans and a Genetic 
      Mouse Model of High Methamphetamine Intake.
PG  - 169-177
LID - 10.1159/000485129 [doi]
AB  - BACKGROUND: Methamphetamine (MA) abuse causes immune dysfunction and 
      neuropsychiatric impairment. The mechanisms underlying these deficits remain 
      unidentified. METHODS: The effects of MA on anxiety-like behavior and immune 
      function were investigated in mice selectively bred to voluntarily consume high 
      amounts of MA [i.e., MA high drinking (MAHDR) mice]. MA (or saline) was 
      administered to mice using a chronic (14-day), binge-like model. Performance in 
      the elevated zero maze (EZM) was determined 5 days after the last MA dose to 
      examine anxiety-like behavior. Cytokine and chemokine expressions were measured 
      in the hippocampus using quantitative polymerase chain reaction (qPCR). Human 
      studies were also conducted to evaluate symptoms of anxiety using the General 
      Anxiety Disorder-7 Scale in adults with and without a history of MA dependence. 
      Plasma samples collected from human research participants were used for 
      confirmatory analysis of murine qPCR results using an enzyme-linked immunosorbent 
      assay. RESULTS: During early remission from MA, MAHDR mice exhibited increased 
      anxiety-like behavior on the EZM and reduced expression of chemokine (C-C motif) 
      ligand 3 (ccl3) in the hippocampus relative to saline-treated mice. Human adults 
      actively dependent on MA and those in early remission had elevated symptoms of 
      anxiety as well as reductions in plasma levels of CCL3, relative to adults with 
      no history of MA abuse. CONCLUSIONS: The results highlight the complex effects of 
      MA on immune and behavioral function and suggest that alterations in CCL3 
      signaling may contribute to the mood impairments observed during remission from 
      MA addiction.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - Huckans, Marilyn
AU  - Huckans M
AD  - Research and Development Service, VA Portland Health Care System, Portland, 
      Oregon, USA.
AD  - Department of Psychiatry, Oregon Health and Science University, Portland, Oregon, 
      USA.
AD  - Mental Health and Clinical Neurosciences Division, VA Portland Health Care 
      System, Portland, Oregon, USA.
AD  - Methamphetamine Abuse Research Center, Oregon Health and Science University, 
      Portland, Oregon, USA.
FAU - Wilhelm, Clare J
AU  - Wilhelm CJ
AD  - Research and Development Service, VA Portland Health Care System, Portland, 
      Oregon, USA.
AD  - Department of Psychiatry, Oregon Health and Science University, Portland, Oregon, 
      USA.
FAU - Phillips, Tamara J
AU  - Phillips TJ
AD  - Research and Development Service, VA Portland Health Care System, Portland, 
      Oregon, USA.
AD  - Methamphetamine Abuse Research Center, Oregon Health and Science University, 
      Portland, Oregon, USA.
AD  - Department of Behavioral Neuroscience, Oregon Health and Science University, 
      Portland, Oregon, USA.
FAU - Huang, Elaine T
AU  - Huang ET
AD  - Research and Development Service, VA Portland Health Care System, Portland, 
      Oregon, USA.
AD  - Methamphetamine Abuse Research Center, Oregon Health and Science University, 
      Portland, Oregon, USA.
FAU - Hudson, Rebekah
AU  - Hudson R
AD  - Research and Development Service, VA Portland Health Care System, Portland, 
      Oregon, USA.
FAU - Loftis, Jennifer M
AU  - Loftis JM
AD  - Research and Development Service, VA Portland Health Care System, Portland, 
      Oregon, USA.
AD  - Department of Psychiatry, Oregon Health and Science University, Portland, Oregon, 
      USA.
AD  - Methamphetamine Abuse Research Center, Oregon Health and Science University, 
      Portland, Oregon, USA.
LA  - eng
GR  - U01 DA041579/DA/NIDA NIH HHS/United States
GR  - P50 DA018165/DA/NIDA NIH HHS/United States
GR  - I01 BX002106/BX/BLRD VA/United States
GR  - I01 BX002061/BX/BLRD VA/United States
GR  - P60 AA010760/AA/NIAAA NIH HHS/United States
GR  - RC1 DA028537/DA/NIDA NIH HHS/United States
PT  - Journal Article
DEP - 20180118
PL  - Switzerland
TA  - Neuropsychobiology
JT  - Neuropsychobiology
JID - 7512895
RN  - 0 (CCL3 protein, human)
RN  - 0 (Ccl3 protein, mouse)
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Chemokine CCL3)
RN  - 0 (RNA, Messenger)
RN  - 44RAL3456C (Methamphetamine)
SB  - IM
MH  - Adult
MH  - Amphetamine-Related Disorders/*metabolism/*psychology/therapy
MH  - Animals
MH  - Anxiety/*chemically induced/*metabolism
MH  - Central Nervous System Stimulants/administration & dosage
MH  - Chemokine CCL3/*blood/*metabolism
MH  - Disease Models, Animal
MH  - Female
MH  - Follow-Up Studies
MH  - Genetic Predisposition to Disease
MH  - Hippocampus/drug effects/metabolism
MH  - Humans
MH  - Male
MH  - Methamphetamine/administration & dosage
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred DBA
MH  - Middle Aged
MH  - RNA, Messenger/metabolism
MH  - Treatment Outcome
PMC - PMC5911417
MID - NIHMS944126
OTO - NOTNLM
OT  - Anxiety
OT  - Genetic model
OT  - Hippocampus
OT  - Humans
OT  - Immune system
OT  - Methamphetamine
OT  - Rodents
COIS- Disclosure Statement No conflict of interest declared.
EDAT- 2018/02/07 06:00
MHDA- 2018/09/12 06:00
PMCR- 2018/04/22
CRDT- 2018/02/07 06:00
PHST- 2017/05/18 00:00 [received]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2018/09/12 06:00 [medline]
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/04/22 00:00 [pmc-release]
AID - 000485129 [pii]
AID - 10.1159/000485129 [doi]
PST - ppublish
SO  - Neuropsychobiology. 2017;75(4):169-177. doi: 10.1159/000485129. Epub 2018 Jan 18.